ducovest

FHI-B:CA:TSX-CI Health Care Giants Covered Call ETF (CAD)

ETF | Others |

Last Closing

CAD 13.34

Change

0.00 (0.00)%

Market Cap

CAD 0.05B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Currency: CAD

Country : Canada

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

N/A

 CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

 CAD 5.38B
XEQT:CA iShares Core Equity Portfolio

N/A

 CAD 5.22B
PHYS-U:CA Sprott Physical Gold Trust

N/A

 CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

N/A

 CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

N/A

 CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

N/A

 CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

N/A

 CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

N/A

 CAD 2.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

 CAD 2.68B

ETFs Containing FHI-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.25% 44% F 45% F
Dividend Return 3.47% 65% D 53% F
Total Return 12.73% 45% F 45% F
Trailing 12 Months  
Capital Gain 10.71% 38% F 40% F
Dividend Return 5.28% 73% C 64% D
Total Return 15.98% 41% F 42% F
Trailing 5 Years  
Capital Gain 23.75% 55% F 58% F
Dividend Return 36.82% 88% B+ 90% A-
Total Return 60.56% 72% C 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 3.89% 60% D- 49% F
Dividend Return 4.21% 60% D- 45% F
Total Return 0.31% 86% B+ 32% F
Risk Return Profile  
Volatility (Standard Deviation) 5.03% 79% B- 91% A-
Risk Adjusted Return 83.66% 95% A 90% A-
Market Capitalization 0.05B 45% F 23% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.